FORM PTO-1449					SERIAL NO.		10/650,60	10/650,608	
INFORMATION DISCLOSURE STATEMENT					FILING DATE			28 Aug 2003	
					APPLICANT			Jean-Paul Cassart et al	
					GROUP			1642	
					EXAMINER		Min-Tam Davis		
					ATTORNEY DOCKET NO.		BC45300-1US		
U.S. PATENT DOCUMENTS									
Examiner Initials		Patent Number	Issue Date		Name	Class	Subclass	Filing Date If Appropriate	
	-								
	-								
	-								
	-								
			FORTIC		n n o evis ensume				
	FOREIGN PATENT DOCUMENTS								
		Document	Publication		a		6.1.1	Translation Yes No	
	-	Number	Date	9	Country	Class	Subclass	100 100	
	-								
	-								
	-								
	-								
		<u> </u>							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)									
	1	Arteaga (2002) "Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastitic breast cancer," <i>Breast Cancer Res.</i> 5:96-100.							
	2	Mitchell (2002) "Cancer vaccines, a critical reviewPart II," Curr Opin Investig Drugs. 3:150-8							
	3	Reiter (1998) "Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer," PNAS 95:1735-1740.							
	4		Ross (2002) "Prostate Stem Cell Antigen as Therapy Target: Tissue Expression and in Vivo						
			Efficacy of an Immunoconjugate," Cancer Research 62:2546-2553						
	5	Garcia-Hernandez (2008) "Prostate Stem Cell Antigen Vaccination Induces a Long-term Protective							
			nse against Pro	state Cand	er in the Absence	e of Autoimm	nunity," <i>Canc</i>	er Research	
	68:861-869. 6 GlaxoSmithKline Biologicals, No. 004, "Antigen Specific Concer Immunotherapsutics: Educating								
	6	** ClaxoSmithKiim	e Biologicals, N	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	rtiger Spesifie S e	Meer-Immun	<u>etherepoutie</u>	s:Educating	
		the patient's immune defense to fight cancer" (2007). Pages? reviewed but cannot be							
	ļ	published. /TD/							
	ļ	pr (1447							
	ļ								
EXAMINE	R /Mii	nh Tam Davis/ (11/21/2008)			DATE	CONSIDERE	D	
EXAMINE	R: Initia	al if citation conside	ered, whether or i	not citation	is in conformance	with MPEP §	609; Draw lin	e through	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.